Accelrys
Accelrys, now operating as BIOVIA under Dassault Systèmes, provides enterprise scientific informatics software for life sciences, chemicals, and materials R&D, covering molecular modeling, lab informatics, and AI-driven discovery for large pharmaceutical, consumer goods, and industrial customers.
- Company typePrivate
- Founded1987
- HeadquartersSan Diego, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
What Accelrys does
Accelrys was a San Diego-headquartered scientific informatics software company founded in the late 1980s (originally as a platform enabling researchers in life sciences, chemicals, and materials to manage scientific data, automate workflows, and run computational modeling). Its core technology stack centered on products such as Pipeline Pilot for scientific workflow automation, Discovery Studio and Materials Studio for molecular and materials modeling, ONE Lab for laboratory execution, and electronic laboratory notebooks for regulated R&D environments. The company built capabilities through multiple acquisitions of Symyx Technologies, Contur Software, VelQuest, Aegis Analytical, ChemSW, and Qumas, layering in lab informatics, quality management, and analytical data handling on top of its modeling core.
In April 2014 Accelrys was acquired by Dassault Systèmes and ceased to trade as a standalone public entity on NASDAQ (ticker ACCL). Its offerings are now sold under the BIOVIA brand within Dassault's 3DEXPERIENCE platform, covering molecular modeling, materials simulation, lab informatics, quality and regulatory compliance, and increasingly AI-driven scientific discovery. The 3DEXPERIENCE platform combines BIOVIA, CATIA, SOLIDWORKS, SIMULIA, and other 3D design / engineering / simulation applications, and BIOVIA contributes the scientific R&D layer for industries including pharmaceuticals, biotechnology, chemicals, consumer goods, aerospace, and automotive.
The business model is enterprise B2B software: customers license BIOVIA modules on subscription or term basis, consume professional services for deployment and validation, and engage Dassault for ongoing support. Pricing is anchored to per-seat, per-site, or enterprise-wide agreements; revenue mechanics therefore depend heavily on multi-year enterprise contracts, large-account renewals, and validation-heavy regulated deployments. Leadership pedigree includes co-founder Alejandro Zaffaroni (a biotechnology entrepreneur and investor), co-founder Peter G. Schultz (a noted chemist), and former CEO Max Carnecchia; the company has historically emphasized GxP compliance, ISO certifications, and integration with enterprise LIMS/ERP/PLM systems. Customer concentration is moderate, with a roster of named enterprise users spanning Pfizer, AstraZeneca, Amgen, Bayer, Sanofi, Gilead, L'Oréal, P&G, Unilever, Airbus, GM, Tesla, Dow Chemical, and Aboca across pharmaceuticals, consumer goods, automotive, and chemicals. In 2025, BIOVIA announced a strategic partnership with NVIDIA to integrate accelerated computing and inference technology into BIOVIA Scientific AI, alongside new offerings including AI-Ready Lab, AI-Powered Formulation Development, Generative Therapeutics Design, and Virtual Twin Experiences, positioning the platform for the growing enterprise scientific AI market. However, as a fully integrated subsidiary of a publicly traded French parent, BIOVIA does not separately disclose segmental revenue, headcount, or capital allocation, which limits standalone financial visibility. The company was originally venture-backed before its NASDAQ IPO and went through multiple funding and acquisition cycles prior to the Dassault transaction. The intellectual property estate is anchored by long-lived scientific algorithms including the COSMO-RS quantum-chemistry thermodynamics framework, continued development of which supports differentiation in formulation and process chemistry applications. Go-to-market remains primarily direct enterprise sales supplemented by an academic licensing program targeting universities to build long-term developer adoption of the BIOVIA stack. Geographic reach is global via Dassault Systèmes' commercial footprint, and the underlying computational biology and chemistry software market is in a structural growth phase driven by AI adoption in R&D. As of the most recent available inputs, named recent strategic actions have been the 2025 NVIDIA partnership and the 2025 AI product launches under the BIOVIA brand, with the 2014 Dassault acquisition remaining the single most consequential corporate event in Accelrys' history. No new standalone funding events, executive transitions, or divestitures are reported in the input beyond these events.
Accelrys firmographics
Firmographics- Name
- Accelrys
- Legal name
- Accelrys Inc.
- Website
- https://accelrys.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Accelrys, now operating as BIOVIA under Dassault Systèmes, provides enterprise scientific informatics software for life sciences, chemicals, and materials R&D, covering molecular modeling, lab informatics, and AI-driven discovery for large pharmaceutical, consumer goods, and industrial customers.
- Ownership category
- akta.pro rank
Accelrys industry classification
Industry- Product category
- Scientific Informatics Software
- NAICS
- Software Publishers (513210), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity) (HLAHAAAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)
Keywords
Where Accelrys is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Accelrys business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licenses and Subscriptions: BIOVIA generates revenue primarily through software licensing and subscription fees for its scientific software portfolio including Discovery Studio, Materials Studio, Pipeline Pilot, and ONE Lab. Full versions require paid licenses with academic institutions eligible for discounted pricing. Free visualizer versions available for basic molecular structure viewing.
- Professional Services: Dassault Systèmes provides services offerings including implementation, training, and consulting services for BIOVIA products.
- Contract Research Services: BIOVIA offers contract research services providing specialized scientific research capabilities to clients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free Visualizer Version |
| Subscription | Annual | Full Commercial License |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels10 records
Accelrys product offering
Product offeringCore offering
Accelrys develops and licenses scientific informatics software and services for life sciences, chemicals, and materials research R&D. Its portfolio combines molecular modeling and simulation, laboratory informatics, AI-driven scientific data management, and contract research services used by pharmaceutical, biotechnology, consumer products, aerospace, automotive, and specialty chemicals organizations.
Product overview
BIOVIA, a brand of Dassault Systèmes (which acquired Accelrys in 2014), offers a comprehensive scientific software portfolio organized around the 3DEXPERIENCE BIOVIA platform — a unified, collaborative environment connecting all solutions from molecule to manufacturing. The core portfolio includes scientific data management and AI capabilities through BIOVIA Scientific AI; molecular modeling via BIOVIA Discovery Studio and Materials Studio; laboratory management via BIOVIA ONE Lab (spanning LIMS, ELN, and instrument management); data processing via Pipeline Pilot; and specialized solutions for formulation development, QC automation, biotherapeutics, and virtual twin experiences. Disciplines span Biosciences, Laboratory Informatics, Materials Science & Engineering, Regulatory Management, Scientific Informatics, and Quality Management.
Differentiator
Problem solved
Functional benefit
Products and services
- 3DEXPERIENCE BIOVIA Unified scientific informatics platform combining molecular modeling, simulation, laboratory informatics, and scientific data management on Dassault Systèmes' 3DEXPERIENCE platform for enterprise R&D.
- BIOVIA Discovery Studio
Quantifiable outcome
- Saved Pfizer scientists 5-7 hours per week through automated error checking and data collection
- +1 more outcomes
Companies that use Accelrys
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles4 records
Accelrys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
Accelrys partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreStrategic partnership combining NVIDIA-accelerated AI inference with BIOVIA's scientific AI and modeling capabilities. Enables design of impossible therapeutics and high-performance materials within a collaborative 3D environment. Partnership focuses on next-generation AI-powered computational biology and molecular design.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Accelrys competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Accelrys social profiles
Digital presenceAccelrys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accelrys leadership team
Management profileNumber of profiles
Profiles6 records
Accelrys subsidiaries and ownership
Company hierarchySubsidiaries1 record
Accelrys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accelrys M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accelrys
What does Accelrys do?
Accelrys develops and licenses scientific informatics software and services for life sciences, chemicals, and materials research R&D. Its portfolio combines molecular modeling and simulation, laboratory informatics, AI-driven scientific data management, and contract research services used by pharmaceutical, biotechnology, consumer products, aerospace, automotive, and specialty chemicals organizations.
Is Accelrys a public or private company?
Accelrys is a private company. It is classified as corporate owned and is currently acquired.
When was Accelrys founded?
Accelrys was founded in 1987. It employs 501 to 1,000 people.
Where is Accelrys based?
Accelrys is headquartered in San Diego, United States, in the North America region.
How does Accelrys make money?
Three revenue lines are on record. Software Licenses and Subscriptions are the primary driver. The others are professional Services and contract Research Services.
Does Accelrys have an API?
No public API is recorded for Accelrys.
What industry is Accelrys in?
Accelrys's product category is Scientific Informatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 513210 and its SIC code is 7372.